Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Intermittierende Theta-Burst-Stimulation zur Verbesserung negativer Symptome und Kognition bei Schizophrenie (ITBS-NKS-2024)

15. September 2026 aktualisiert von: Schülke, Rasmus Dr., Hannover Medical School

Intermittierende Theta-Burst-Stimulation Zur Verbesserung Von Negativsymptomatik Und Kognition Bei Schizophrenie

The planned randomized, sham-controlled, double-blind, monocentric study aims to evaluate the effectiveness of intermittent Theta-Burst Stimulation (iTBS) on negative symptoms and cognitive deficits in schizophrenia. Both the cerebellar vermis and the left dorsolateral prefrontal cortex will be stimulated successively within the same session.

The goal of this trial is to learn if intermittent theta-burst stimulation (iTBS) of the cerebellum and the left dorsolateral prefrontal cortext (DLPFC) can treat negative symptoms and improve cognition in patients with schizophrenia. The main question it aims to answer is:

Does iTBS of the cerebellum and the left DLPFC improve negative symptoms in patients with schizophrenia? Researchers will compare iTBS to sham stimulation to see if iTBS improves negative symptoms.

Participants will:

  • Receive 10 sessions of iTBS over the course of 2 weeks
  • Undergo extensive examination before iTBS treatment, immediately after iTBS treatment and 4 weeks after iTBS treatment. The examination includes assessment of negative symptoms; psychometric assessment of cognition, social cognition, depressive symptoms; functional magnetic resonance imaging; assessment of eye movements; blood and saliva sampling; assessment of adverse events and stimulation associated sensations.

The study thus seeks to determine whether iTBS of the fronto-cerebellar network might improve negative symptoms and cognition by altering the network's functional activity. Additionally, it will investigate whether a pro-inflammatory cytokine profile could affect iTBS outcomes and whether inflammatory markers could be affected by iTBS.

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

60

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • Lower Saxony
      • Hanover, Lower Saxony, Deutschland, 30625
        • Rekrutierung
        • Hannover Medical School
        • Kontakt:
        • Hauptermittler:
          • Rasmus Schülke, MD (Dr. med.)

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 65 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Diagnosis of schizophrenia (ICD-10: F20.-)
  • Age: 18-65 years
  • Ability to give informed consent
  • Signed informed consent form

Exclusion Criteria:

  • Any electronic implants
  • Non-MRI-compatible metal implants (e.g., pacemaker, cochlear implant, insulin pump, metal fragment injuries, work in the metal-processing industry)
  • Non-TMS-compatible metal implants (compatible items include: earrings, piercings, dental fillings, crowns, implants)
  • Claustrophobia
  • Epilepsy
  • History of traumatic brain injury within the last 3 months
  • History of stroke
  • Active central nervous system (CNS) infection
  • History of CNS infection within the last 3 months
  • Pregnancy
  • Current drug, medication, or alcohol abuse
  • Simultaneous participation in another clinical trial
  • Planned changes in psychopharmacological medication within the next 2 weeks
  • Severe physical illnesses that could endanger the patient, affect the examinations or make the MRI scanning cause additional burden

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Doppelt

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: iTBS

Active intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Schein-Komparator: Sham iTBS

Sham intermittent theta-burst stimulation of the cerebellar vermis and the left dorsolateral prefrontal cortex

Sham intermittent theta-burst stimulation, applied sequentially to the cerebellar vermis and the left dorsolateral prefrontal cortex

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in negative symptoms
Zeitfenster: From enrollment to the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to the end of iTBS treatment

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Change in negative symptoms at 4-week follow-up
Zeitfenster: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Change in negative symptoms, measured with the Clinical Assessment Interview for Negative Symptoms (CAINS). Higher CAINS scores correspond to more negative symptoms. The minimum total score is 0 points, the maximum total score is 52 points.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Speech-gesture rating task
Zeitfenster: From enrollment to the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task.

From enrollment to the end of iTBS treatment
Speech-gesture rating task at 4-week follow-up
Zeitfenster: From enrollment to follow-up 4 weeks after the end of iTBS treatment

Accuracy and speed of evaluations in the Speech-Gesture Rating Task at 4-week follow-up.

From enrollment to follow-up 4 weeks after the end of iTBS treatment
Eye-Tracking Task
Zeitfenster: From enrollment to the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task.

From enrollment to the end of iTBS treatment
Eye-Tracking Task at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Changes in eye movements in the Eye-Tracking Task at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test.

From enrollment to 4 weeks after the end of iTBS treatment
Reading the Mind in the Eyes Test at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Reading the Mind in the Eyes Test at 4-week follow-up.

From enrollment to 4 weeks after the end of iTBS treatment
N-Back Test
Zeitfenster: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index).

From enrollment to the end of iTBS treatment
N-Back Test at 4-week follow-up
Zeitfenster: From enrollment to the end of iTBS treatment

Working memory performance in the N-Back Test (sensitivity index) 4 weeks after the end of iTBS treatment.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity
Zeitfenster: From enrollment to the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to the end of iTBS treatment
FMRI: Resting-state functional connectivity at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Changes in resting-state functional connectivity in functional magnetic resonance imaging. Focus on connectivity between cerebellar vermis and DLPFC.

From enrollment to 4 weeks after the end of iTBS treatment
FMRI: Task-related functional connectivity
Zeitfenster: From enrollment to the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to the end of iTBS treatment
FMRI: Task-related functional connectivity at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Changes in task-related functional connectivity in functional magnetic resonance imaging, for the N-Back-task and the speech-gesture rating task.

From enrollment to 4 weeks after the end of iTBS treatment
Inflammatory cytokines
Zeitfenster: From enrollment to the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to the end of iTBS treatment
Inflammatory cytokines at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of inflammatory cytokines (especially IL-6 and TNF-α) in serum and saliva.

From enrollment to 4 weeks after the end of iTBS treatment
Stimulation-associated perceptions
Zeitfenster: From the beginning of each iTBS stimulation to after the end of each iTBS stimulation

Stimulation-associated perceptions, measured using the TMS Adverse Events and Associated Sensations Questionnaire (TMSensQ, Section IV), after each iTBS session.

From the beginning of each iTBS stimulation to after the end of each iTBS stimulation
Therapy dropout rate
Zeitfenster: From the beginning of iTBS treatment to the end of iTBS treatment

Therapy dropout rate (i.e. study termination).

From the beginning of iTBS treatment to the end of iTBS treatment
Serious Adverse Events (SAEs)
Zeitfenster: From the beginning of iTBS treatment to the end of iTBS treatment

Serious Adverse Events (SAEs), measured using TMSensQ (Section V).

From the beginning of iTBS treatment to the end of iTBS treatment
Self-reported depression: BDI-II
Zeitfenster: From enrollment to the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to the end of iTBS-treatment
Self-reported depression at 4-week follow-up: BDI-II
Zeitfenster: From enrollment to 4 weeks after the end of iTBS-treatment

Self-reported depression, measured using the Beck Depression Inventory-II (BDI-II). Higher scores correspond to more depressive symptoms. The minimum total score is 0 points, the maximum total score is 63 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Self-rated gesture perception and production: BAG
Zeitfenster: From enrollment to the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to the end of iTBS-treatment
Self-rated gesture perception and production at 4-week follow-up: BAG
Zeitfenster: From enrollment to 4 weeks after the end of iTBS-treatment

Change in self-rated gesture perception and production, measured using the Brief Assessment of Gestures (BAG) questionnaire. Higher BAG scores correspond to greater engagement with or reliance on gestures in communication and indicate stronger tendencies to produce or perceive gestures effectively in different contexts. The minimum total score is 12 points, the maximum total score is 60 points.

From enrollment to 4 weeks after the end of iTBS-treatment
Epigenetic changes of neurotrophic and immunological factors
Zeitfenster: From enrollment to the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to the end of iTBS treatment
Epigenetic changes of neurotrophic and immunological factors at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Exploratory molecular biological investigations focusing on neurotrophic (e.g., BDNF, VEGF, GDNF) and immunological (e.g., TNF-alpha, IL-6, t-PA, S100A10) factors.

From enrollment to 4 weeks after the end of iTBS treatment
Concentrations of markers of neuronal damage
Zeitfenster: From enrollment to the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to the end of iTBS treatment
Concentrations of markers of neuronal damage at 4-week follow-up
Zeitfenster: From enrollment to 4 weeks after the end of iTBS treatment

Concentrations of markers of neuronal damage (e.g., NSE, S100-β) in serum.

From enrollment to 4 weeks after the end of iTBS treatment

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Ermittler

  • Hauptermittler: Rasmus Schülke, MD (Dr. med.), Hannover Medical School

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. April 2025

Primärer Abschluss (Geschätzt)

31. Dezember 2026

Studienabschluss (Geschätzt)

31. Dezember 2026

Studienanmeldedaten

Zuerst eingereicht

14. Dezember 2024

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

14. Dezember 2024

Zuerst gepostet (Tatsächlich)

18. Dezember 2024

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

18. September 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

15. September 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • 11473_BO_S_2024

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

UNENTSCHIEDEN

Beschreibung des IPD-Plans

Whether IPD may be shared has not yet been decided. IPD might not be shared due to data protection laws.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Produkt, das in den USA hergestellt und aus den USA exportiert wird

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .